probucol has been researched along with Diabetic Glomerulosclerosis in 12 studies
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Probucol was administered by gavage and the contrast diatrizoate (60%) was injected via femoral vein." | 5.51 | Probucol Protects Against Contrast-Induced Acute Kidney Injury via the Extracellular Signal-Regulated Kinases 1 and 2 (ERK1/2)/JNK-Caspase 3 Pathway in Diabetic Rats. ( Chen, J; Jiao, Z; Li, G; Liu, T; Liu, Y; Ma, X; Tse, G; Yuan, R, 2019) |
| " The 24-h proteinuria levels were significantly reduced in the probucol + telmisartan compared with telmisartan group." | 5.22 | Telmisartan combined with probucol effectively reduces urinary protein in patients with type 2 diabetes: A randomized double-blind placebo-controlled multicenter clinical study. ( Cai, G; Chen, X; Guan, X; Li, J; Li, W; Liu, M; Liu, W; Liu, Y; Lun, L; Wang, Y; Wu, H; Yao, H; Yin, S; Zhang, J; Zheng, Y; Zhou, C; Zhu, H; Zhuang, X, 2016) |
| "To determine the effect of probucol on urine albumin excretion in type 2 diabetes mellitus patients with albuminuria using angiotensin-converting enzyme inhibitors or angiotensin receptor blockers." | 5.22 | Probucol in Albuminuric Type 2 Diabetes Mellitus Patients on Renin-Angiotensin System Blockade: A 16-Week, Randomized, Double-Blind, Placebo-Controlled Trial. ( Baik, SH; Cha, BS; Choi, SH; Chung, CH; Han, KA; Hwang, YC; Jin, SM; Ko, SH; Lee, HW; Lee, IK; Lee, MK; Nam, MS; Park, IeB; Park, TS; Rhee, EJ; Sohn, TS; Yu, JM, 2016) |
| "Probucol has antioxidant as well as cholesterol-lowering effects." | 2.78 | Probucol suppresses initiation of chronic hemodialysis therapy and renal dysfunction-related death in diabetic nephropathy patients: Sakura study. ( Ban, N; Endo, K; Kawana, H; Miyashita, Y; Murano, T; Nagayama, D; Nagumo, A; Ohira, M; Oyama, T; Saiki, A; Sakuma, K; Sasaki, H; Shirai, K; Suzuki, Y; Tatsuno, I; Yamaguchi, T; Yamamura, S, 2013) |
| "Probucol has antioxidant and cholesterol-lowering effects." | 2.72 | Probucol delays progression of diabetic nephropathy. ( Endo, K; Ito, Y; Koide, N; Miyashita, Y; Ohira, M; Otsuka, M; Oyama, T; Saiki, A; Sasaki, H; Shirai, K; Takeyoshi, M, 2006) |
| "Probucol was administered by gavage and the contrast diatrizoate (60%) was injected via femoral vein." | 1.51 | Probucol Protects Against Contrast-Induced Acute Kidney Injury via the Extracellular Signal-Regulated Kinases 1 and 2 (ERK1/2)/JNK-Caspase 3 Pathway in Diabetic Rats. ( Chen, J; Jiao, Z; Li, G; Liu, T; Liu, Y; Ma, X; Tse, G; Yuan, R, 2019) |
| "Probucol is an anti-hyperlipidemic agent and a potent antioxidant drug that can delay progression of diabetic nephropathy (DN) and reverses renal oxidative stress in diabetic animal models; however, the mechanisms underlying these effects remain unclear." | 1.46 | Probucol ameliorates renal injury in diabetic nephropathy by inhibiting the expression of the redox enzyme p66Shc. ( Chen, C; Han, Y; Hu, C; Kanwar, YS; Liu, F; Liu, Y; Sun, L; Xiao, L; Xiong, X; Yang, S; Zhan, M; Zhao, L; Zhou, Z; Zhu, X, 2017) |
| "Probucol can suppress cell proliferation, down-regulate mRNA and protein levels of TGF-beta1 and CTGF in HMCs treated with high glucose." | 1.36 | Janus kinase 2/signal transducers and activators of transcription signal inhibition regulates protective effects of probucol on mesangial cells treated with high glucose. ( Du, J; Fan, Q; Feng, J; Liu, X; Luo, J; Ma, J; Wang, J; Wang, L; Yao, L; Zhou, H, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 8 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yang, S | 1 |
| Zhao, L | 1 |
| Han, Y | 1 |
| Liu, Y | 3 |
| Chen, C | 1 |
| Zhan, M | 1 |
| Xiong, X | 1 |
| Zhu, X | 1 |
| Xiao, L | 1 |
| Hu, C | 1 |
| Liu, F | 1 |
| Zhou, Z | 1 |
| Kanwar, YS | 1 |
| Sun, L | 1 |
| Ma, X | 1 |
| Jiao, Z | 1 |
| Chen, J | 1 |
| Li, G | 1 |
| Liu, T | 1 |
| Tse, G | 1 |
| Yuan, R | 1 |
| Zhu, H | 1 |
| Chen, X | 1 |
| Cai, G | 1 |
| Zheng, Y | 1 |
| Liu, M | 1 |
| Liu, W | 1 |
| Yao, H | 1 |
| Wang, Y | 2 |
| Li, W | 1 |
| Wu, H | 1 |
| Lun, L | 1 |
| Zhang, J | 1 |
| Guan, X | 1 |
| Yin, S | 1 |
| Zhuang, X | 1 |
| Li, J | 1 |
| Zhou, C | 1 |
| Liu, G | 1 |
| Ji, W | 1 |
| Huang, J | 1 |
| Liu, L | 1 |
| Jin, SM | 1 |
| Han, KA | 1 |
| Yu, JM | 1 |
| Sohn, TS | 1 |
| Choi, SH | 1 |
| Chung, CH | 1 |
| Park, IeB | 1 |
| Rhee, EJ | 1 |
| Baik, SH | 1 |
| Park, TS | 1 |
| Lee, IK | 1 |
| Ko, SH | 1 |
| Hwang, YC | 1 |
| Cha, BS | 1 |
| Lee, HW | 1 |
| Nam, MS | 1 |
| Lee, MK | 1 |
| Du, J | 1 |
| Wang, L | 1 |
| Liu, X | 1 |
| Zhou, H | 1 |
| Fan, Q | 1 |
| Luo, J | 1 |
| Yao, L | 1 |
| Wang, J | 1 |
| Feng, J | 1 |
| Ma, J | 1 |
| Duan, SB | 1 |
| Liu, GL | 1 |
| Wang, YH | 1 |
| Zhang, JJ | 1 |
| Endo, K | 2 |
| Saiki, A | 2 |
| Yamaguchi, T | 1 |
| Sakuma, K | 1 |
| Sasaki, H | 2 |
| Ban, N | 1 |
| Kawana, H | 1 |
| Nagayama, D | 1 |
| Nagumo, A | 1 |
| Ohira, M | 2 |
| Oyama, T | 2 |
| Murano, T | 1 |
| Miyashita, Y | 2 |
| Yamamura, S | 1 |
| Suzuki, Y | 1 |
| Shirai, K | 2 |
| Tatsuno, I | 1 |
| Koide, N | 1 |
| Otsuka, M | 1 |
| Takeyoshi, M | 1 |
| Ito, Y | 1 |
| Soulis-Liparota, T | 1 |
| Cooper, ME | 1 |
| Dunlop, M | 1 |
| Jerums, G | 1 |
| Kim, SS | 1 |
| Gallaher, DD | 1 |
| Csallany, AS | 1 |
| Nishimura, M | 1 |
| Sasaki, T | 1 |
| Ohishi, A | 1 |
| Oishi, M | 1 |
| Kono, S | 1 |
| Totani, Y | 1 |
| Kato, Y | 1 |
| Noto, Y | 1 |
| Misaki, S | 1 |
| Higashi, K | 1 |
| Shimada, F | 1 |
| Wakasugi, H | 1 |
| Inoue, K | 1 |
| Hoshiyama, Y | 1 |
| Yamada, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II, Multicenter, Randomized, Double Blind, Double-dummy, 16-week, Placebo Controlled Study to Evaluate the Efficacy and Safety of Probucol in Patients With Nephropathy Due to Type 2 Diabetes.[NCT01726816] | Phase 2 | 126 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 trials available for probucol and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Telmisartan combined with probucol effectively reduces urinary protein in patients with type 2 diabetes: A randomized double-blind placebo-controlled multicenter clinical study.
Topics: Aged; Analysis of Variance; Anticholesteremic Agents; Benzimidazoles; Benzoates; Blood Glucose; Chol | 2016 |
Probucol in Albuminuric Type 2 Diabetes Mellitus Patients on Renin-Angiotensin System Blockade: A 16-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inh | 2016 |
Probucol suppresses initiation of chronic hemodialysis therapy and renal dysfunction-related death in diabetic nephropathy patients: Sakura study.
Topics: Aged; Albuminuria; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Creati | 2013 |
Probucol delays progression of diabetic nephropathy.
Topics: Aged; Albuminuria; Anticholesteremic Agents; Blood Pressure; Cholesterol; Cholesterol, HDL; Creatini | 2006 |
Angiotensin-converting enzyme inhibitors and probucol suppress the time-dependent increase in urinary Type IV collagen excretion of Type II diabetes mellitus patients with early diabetic nephropathy.
Topics: Acetylglucosaminidase; Adult; Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antioxida | 2001 |
7 other studies available for probucol and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Probucol ameliorates renal injury in diabetic nephropathy by inhibiting the expression of the redox enzyme p66Shc.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Anticholesteremic Agents; Antioxidants; Cell Line; Di | 2017 |
Probucol Protects Against Contrast-Induced Acute Kidney Injury via the Extracellular Signal-Regulated Kinases 1 and 2 (ERK1/2)/JNK-Caspase 3 Pathway in Diabetic Rats.
Topics: Acute Kidney Injury; Animals; Antioxidants; Apoptosis; Caspase 3; Contrast Media; Diabetes Mellitus, | 2019 |
4-HNE expression in diabetic rat kidneys and the protective effects of probucol.
Topics: Aldehydes; Animals; Antioxidants; Biomarkers; Blotting, Western; Diabetes Mellitus, Experimental; Di | 2016 |
Janus kinase 2/signal transducers and activators of transcription signal inhibition regulates protective effects of probucol on mesangial cells treated with high glucose.
Topics: Antioxidants; Cell Line; Cell Proliferation; Connective Tissue Growth Factor; Diabetic Nephropathies | 2010 |
Epithelial-to-mesenchymal transdifferentiation of renal tubular epithelial cell mediated by oxidative stress and intervention effect of probucol in diabetic nephropathy rats.
Topics: Animals; Antioxidants; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Epithelial-Mesenchym | 2012 |
The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat.
Topics: Albuminuria; Aldehyde Reductase; Animals; Antioxidants; Blood Glucose; Body Weight; Butylated Hydrox | 1995 |
Vitamin E and probucol reduce urinary lipophilic aldehydes and renal enlargement in streptozotocin-induced diabetic rats.
Topics: Aldehydes; Animals; Antioxidants; Ascorbic Acid; Blood Glucose; Diabetes Mellitus, Experimental; Dia | 2000 |